HK Stock Market Move | SHINEWAY PHARM (02877) rose more than 9% in the afternoon as the company participates in the 2026 national medical insurance negotiations with multiple traditional Chinese medicine formulations.

SHINEWAY PHARM (02877) surged over 9% in the afternoon. As of the time of writing, it rose by 8.56%, trading at HKD 8.09, with a transaction volume of HKD 27.3675 million. In terms of news, on September 8, the negotiations for basic medical insurance concluded in the morning, with SHINEWAY PHARM participating in the bidding with several traditional Chinese medicine products, including Shaoyao Gancao Decoction Granules and Taohong Siwu Decoction Granules. Notably, the 2026 version of the National Essential Medicine List was officially implemented on September 1, and SHINEWAY PHARM successfully included four Chinese medicine injections and several exclusive traditional Chinese medicines in the previous selection. SHINEWAY PHARMs interim financial report shows that in the first half of the year, its revenue was RMB 1.181 billion, a year-on-year decrease of 28.5%; net profit for the period was RMB 469 million, a year-on-year decrease of 23.7%; and it intends to distribute a second interim dividend of 80 cents. The group continues to focus on expanding its oral formulations as a key development strategy. In the first six months of 2026, oral products accounted for 72.9% of total sales, while injection products accounted for 27.1% of total sales.